ES2122015T3 - Uso de urodilatina en enfermedades pulmonares y bronquiales. - Google Patents

Uso de urodilatina en enfermedades pulmonares y bronquiales.

Info

Publication number
ES2122015T3
ES2122015T3 ES93912706T ES93912706T ES2122015T3 ES 2122015 T3 ES2122015 T3 ES 2122015T3 ES 93912706 T ES93912706 T ES 93912706T ES 93912706 T ES93912706 T ES 93912706T ES 2122015 T3 ES2122015 T3 ES 2122015T3
Authority
ES
Spain
Prior art keywords
pct
urodilatine
lung
bronchial diseases
date nov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93912706T
Other languages
English (en)
Inventor
Thomas Fluge
Wolf-Georg Forssmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haemopep Pharma GmbH
Original Assignee
Haemopep Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haemopep Pharma GmbH filed Critical Haemopep Pharma GmbH
Application granted granted Critical
Publication of ES2122015T3 publication Critical patent/ES2122015T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2242Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LA UTILIZACION DE UNA PREPARACION FARMACEUTICA, QUE CONTIENE URODILATINA COMO SUSTANCIA ACTIVA Y EVENTUALMENTE SUSTANCIAS ADICIONALES AUXILIARES DE RELLENO HABITUALES, PORTADORAS, O SUSTANCIAS DE DILUCION, PARA EL TRATAMIENTO DE ENFERMEDADES PULMONARES Y/O BRONQUIALES.
ES93912706T 1992-05-15 1993-05-12 Uso de urodilatina en enfermedades pulmonares y bronquiales. Expired - Lifetime ES2122015T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4216133A DE4216133A1 (de) 1992-05-15 1992-05-15 Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen

Publications (1)

Publication Number Publication Date
ES2122015T3 true ES2122015T3 (es) 1998-12-16

Family

ID=6458997

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93912706T Expired - Lifetime ES2122015T3 (es) 1992-05-15 1993-05-12 Uso de urodilatina en enfermedades pulmonares y bronquiales.

Country Status (8)

Country Link
US (1) US5571789A (es)
EP (1) EP0642349B1 (es)
JP (1) JP3172188B2 (es)
AT (1) ATE169225T1 (es)
CA (1) CA2135614C (es)
DE (2) DE4216133A1 (es)
ES (1) ES2122015T3 (es)
WO (1) WO1993023070A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2188143A1 (en) * 1992-12-09 1995-11-02 Wolf-Georg Forssmann Use of brain natriuretic peptides (bnp), phosphorylated urodilatine, phosphorylated cdd/anp and combinations thereof
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
DE19942230C2 (de) * 1999-09-03 2003-09-25 Wolf-Georg Forssmann Verwendung natriuretischer Peptide als antibiotisch wirksame Subsanzen zur Behandlung von bakteriellen Infektionen
DE19951471A1 (de) * 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
EP2510942B1 (en) 2005-04-07 2015-09-02 Cardiorentis AG Use of natriuretic peptide for treating heart failure
US20080181903A1 (en) * 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
AU2008297874A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of secretin and optionally urodilatin as therapeutic agents
EP2078530A1 (en) 2008-01-08 2009-07-15 Pharis Biotec GmbH Use of natriuretic peptides for treating angioedema syndromes
ES2575397T3 (es) * 2007-09-11 2016-06-28 Cardiopep Pharma Gmbh Uso de péptidos natriuréticos para el tratamiento de síndromes de angioedema
WO2009086166A1 (en) * 2007-12-19 2009-07-09 Ekr Therapeutics, Inc. Room temperature stable, lyophilized natriuretic peptide formulations
AU2009292643B2 (en) 2008-09-19 2016-02-18 Nektar Therapeutics Polymer conjugates of therapeutic peptides
JP6097072B2 (ja) * 2012-12-27 2017-03-15 日本航空電子工業株式会社 コネクタ
EA201500765A1 (ru) 2013-01-25 2015-12-30 Кардиорентис Лтд. Способы лечения сердечно-сосудистых заболеваний
WO2016131943A1 (en) 2015-02-20 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes
WO2022029497A1 (en) 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Ularitide for use in methods of treating refractory ascites
WO2022029499A1 (en) 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Methods of treating refractory ascites
CA3217598A1 (en) 2021-05-06 2022-11-10 Par Ingemar Johansson Diagnosing and treating critically ill subjects

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3878231T2 (de) * 1987-03-02 1993-05-27 Bissendorf Peptide Gmbh Neues cadiodilatin-fragment, prozess zu dessen herstellung und dessen anwendung.
DE4117078A1 (de) * 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole

Also Published As

Publication number Publication date
EP0642349A1 (de) 1995-03-15
JP3172188B2 (ja) 2001-06-04
JPH07508722A (ja) 1995-09-28
DE4216133A1 (de) 1993-11-18
CA2135614C (en) 2009-04-28
US5571789A (en) 1996-11-05
ATE169225T1 (de) 1998-08-15
EP0642349B1 (de) 1998-08-05
CA2135614A1 (en) 1993-11-25
WO1993023070A1 (de) 1993-11-25
DE59308848D1 (de) 1998-09-10

Similar Documents

Publication Publication Date Title
ES2122015T3 (es) Uso de urodilatina en enfermedades pulmonares y bronquiales.
IT1255258B (it) Composizioni farmaceutiche per l'applicazione per via nasale.
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
ATE223230T1 (de) Pulmonäre verabreichung des löslichen komplement- receptors typ 1 scr1
DE69727956D1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
MY123354A (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
YU59092A (sh) Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja
MY130157A (en) Method of use for inhibiting bone loss and lowering serum cholesterol
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
EP1153924A3 (en) Substituted 1,3-oxathiolanes with antiviral properties
IL101056A (en) Composition for nasal treatment
ATE242265T1 (de) Auf papillomaviren basierende pharmazeutische präparate
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
DE69706825D1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
NO972623D0 (no) Framasöytisk blanding omfattende lamotrigin
DE69420872D1 (de) Hgh enthaltende pharmazeutische zubereitungen
ATE231522T1 (de) Fragmente eines oberflächenaktiven lungenproteins
KR950700234A (ko) β-페닐이소세린 및 그외 동족체를 제조하는 방법(Method for preparing β-phenylisoserine and analogues thereof)
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
FI934680A0 (fi) Arylmorfolin, framstaellning och anvaending
NO993407L (no) Fremstilling av proteinpreparater med nedsatt aggregatinnhold
EE03876B1 (et) Aminohappe estrit sisaldavad asool-antimükootikumid, nende valmistamine ja kasutamine ning neid sisaldavad farmatseutilised kompositsioonid
NO950177D0 (no) Farmakologisk aktive erivater
AU4944899A (en) New pharmaceutically active compounds

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 642349

Country of ref document: ES